New pill shows promise for Hard-to-Treat lymphoma patients
NCT ID NCT07459608
First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times
Summary
This Phase 2 trial tests lisaftoclax, an oral drug that blocks a protein helping cancer cells survive. It enrolls 75 adults with certain slow-growing lymphomas (CLL, WM, or MZL) who either cannot take standard BTK inhibitors due to health issues or have stopped them due to side effects. Participants take the drug daily in 28-day cycles, and researchers will monitor safety and how well the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lisaftoclax (APG-2575), an oral BCL-2 inhibitor
- What this could lead to
- If successful, this could offer a new oral treatment option for people with certain slow-growing lymphomas who cannot take or have failed other therapies.
- What could go wrong
- This is an early Phase 2 study with only 75 participants and no control group. The drug may not work as hoped or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan cancer hospital
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a new drug combo outsmart resistant lymphomas?
- Can a Three-Drug combo outsmart High-Risk CLL?
- Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
- Can a Two-Drug combo wipe out hidden leukemia cells?